Brand-name drug
Xarelto price, strengths & recalls
Brand of rivaroxaban (generic)
Pharmacies pay $586.18 for 30 tablets of Xarelto 20 mg tablet this week, and from $293.26 to $993.01 across its 6 priced strengths and forms. The generic, rivaroxaban, costs pharmacies from $18.80. It is in shortage (being discontinued). It has 3 recalls on record, none ongoing. Its official label last changed on September 11, 2026.
Being discontinuedMedicare price 2026Brand- Fair cash price
- $684.61
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Xarelto price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 1 mg/mL oral suspension Brand | $3.76 | $3.76 / 1 mL |
| Xarelto kit pack Brand | $19.47 | $993.01 / 51 tablets |
| 2.5 mg tablet Brand | $9.78 | $293.26 / 30 tablets |
| 10 mg tablet Brand | $19.52 | $585.58 / 30 tablets |
| 15 mg tablet Brand | $19.53 | $586.03 / 30 tablets |
| 20 mg tablet Brand | $19.54 | $586.18 / 30 tablets |
The lowest cost per tablet is 2.5 mg tablet at $9.78. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Xarelto vs generic rivaroxaban
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
GenericRivaroxaban pricesMedicare negotiated price
Medicare negotiated a maximum fair price of $197.00 for a 30-day supply of Xarelto, against a 2023 list price of $517.00. It has applied since January 1, 2026.
What this means for patients
- The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
- What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
- Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
- If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Supply status: shortages & recalls
Shortages
- Xarelto, For Suspension, 155 mg (NDC 50458-575-01)Business Decision
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Xarelto
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use XARELTO safely and effectively. See full prescribing information for XARELTO. XARELTO® (rivaroxaban) tablets, for oral use XARELTO® (rivaroxaban) for oral suspension Initial U.S. Approval: 2011
WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
A. Premature discontinuation of XARELTO increases the risk of thrombotic events
Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.3, 2.4), Warnings and Precautions (5.1), and Clinical Studies (14.1)].
B. Spinal/epidural hematoma
Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
use of indwelling epidural catheters
concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
a history of traumatic or repeated epidural or spinal punctures
a history of spinal deformity or spinal surgery
optimal timing between the administration of XARELTO and neuraxial procedures is not known
[see Warnings and Precautions (5.2, 5.3) and Adverse Reactions (6.2)].
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions (5.3)].
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.3)].
WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
(A) Premature discontinuation of XARELTO increases the risk of thrombotic events
Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy. (2.2, 2.3, 5.1, 14.1)
(B) Spinal/epidural hematoma
Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. (5.2, 5.3, 6.2)
Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated. (5.3)
Recent major changes (as listed on the label)
Warnings and Precautions (5.2) | 03/2026 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA022406 · Janssen Pharms
- First approved
- July 1, 2011 (15 years ago)
- Latest approved change
- March 24, 2026
- Approved label
- PDF, Mar 26, 2026
- Generic makers
- 15 approved generic applications on the market
- Last patent listed
- August 17, 2034
Xarelto questions
How much does xarelto cost without insurance?
Pharmacies pay about $586.18 for 30 tablets of xarelto 20 mg tablet ($19.54 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $684.61. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Xarelto?
Yes: rivaroxaban. Pharmacies pay from $18.80 for it. Compare rivaroxaban prices.
Is xarelto in shortage?
Yes. 1 product is listed as in shortage or being discontinued (being discontinued). See which ones.
Has xarelto been recalled?
3 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the xarelto label last change?
The official label was last updated on September 11, 2026 (version 65). See what changed.
Does Medicare have a negotiated price for Xarelto?
Yes: $197.00 for a 30-day supply of Xarelto, from January 1, 2026. What you pay still depends on your plan.
Talk about xarelto
No comments yet. Questions, tips, what worked for you - start the conversation.